Analysts Set Rezolute, Inc. (NASDAQ:RZLT) Target Price at $11.83

Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) has been assigned an average rating of "Buy" from the seven analysts that are covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $11.83.

A number of research analysts have weighed in on RZLT shares. HC Wainwright reiterated a "buy" rating and set a $14.00 target price on shares of Rezolute in a report on Monday, April 28th. Wall Street Zen downgraded Rezolute from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Finally, Wedbush reiterated an "outperform" rating and set a $12.00 target price on shares of Rezolute in a report on Wednesday, May 14th.

Insider Buying and Selling

In other Rezolute news, CFO Daron Evans bought 10,000 shares of the business's stock in a transaction on Wednesday, March 26th. The shares were acquired at an average cost of $2.89 per share, for a total transaction of $28,900.00. Following the purchase, the chief financial officer now owns 237,900 shares in the company, valued at approximately $687,531. This trade represents a 4.39% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Nevan C. Elam bought 12,302 shares of the business's stock in a transaction on Thursday, March 27th. The shares were acquired at an average price of $2.85 per share, for a total transaction of $35,060.70. Following the completion of the purchase, the chief executive officer now owns 224,119 shares in the company, valued at approximately $638,739.15. The trade was a 5.81% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 29,060 shares of company stock worth $83,694 in the last 90 days. Insiders own 18.39% of the company's stock.

Institutional Trading of Rezolute

Several institutional investors have recently added to or reduced their stakes in RZLT. Charles Schwab Investment Management Inc. boosted its stake in Rezolute by 65.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company's stock valued at $112,000 after purchasing an additional 9,000 shares during the last quarter. American Century Companies Inc. boosted its stake in Rezolute by 62.1% during the 4th quarter. American Century Companies Inc. now owns 64,591 shares of the company's stock valued at $316,000 after purchasing an additional 24,742 shares during the last quarter. Geode Capital Management LLC boosted its stake in Rezolute by 5.2% during the 4th quarter. Geode Capital Management LLC now owns 517,014 shares of the company's stock valued at $2,535,000 after purchasing an additional 25,413 shares during the last quarter. ExodusPoint Capital Management LP purchased a new stake in Rezolute during the 4th quarter valued at $277,000. Finally, Barclays PLC purchased a new stake in Rezolute during the 4th quarter valued at $314,000. 82.97% of the stock is currently owned by hedge funds and other institutional investors.

Rezolute Price Performance

RZLT traded down $0.20 during midday trading on Friday, reaching $4.20. 345,000 shares of the company's stock traded hands, compared to its average volume of 594,848. The firm has a fifty day moving average of $3.67 and a two-hundred day moving average of $4.14. The stock has a market capitalization of $359.18 million, a price-to-earnings ratio of -3.44 and a beta of 1.04. Rezolute has a 52 week low of $2.22 and a 52 week high of $6.19.

Rezolute (NASDAQ:RZLT - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). Sell-side analysts forecast that Rezolute will post -0.93 EPS for the current year.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.